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ProphylaxisFiloviruses are the causative agents of lethal hemorrhagic fever in human and non-human primates
(NHP). The family of Filoviridae is composed of three genera, Ebolavirus, Marburgvirus and Cuevavirus.
There are currently no approved vaccines or antiviral therapeutics for the treatment of ﬁlovirus infections
in humans. Passive transfer of neutralizing antibodies targeting the Ebola virus (EBOV) glycoprotein (GP)
has proven effective in protecting mice, guinea pigs and NHP from lethal challenges with EBOV. In this
study, we generated two neutralizing monoclonal antibodies (MAbs), termed S9 and M4 that recognize
the GP of EBOV or multiple strains of Marburg virus (MARV), respectively. We characterized the putative
binding site of S9 as a linear epitope on the glycan cap of the GP1 subunit of the EBOV-GP. The M4 anti-
body recognizes an unknown conformational epitope on MARV-GP. Additionally, we demonstrated the
post-exposure protection potential of these antibodies in both the mouse and guinea pig models of ﬁlo-
virus infection. These data indicate that MAbs S9 and M4 would be good candidates for inclusion in an
antibody cocktail for the treatment of ﬁlovirus infections.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
The family of Filoviridae is composed of three genera, Ebolavirus,
Marburgvirus and Cuevavirus. The Ebolavirus genus can be
subdivided into 5 distinct species: Zaire (EBOV), Sudan (SUDV),
Tai Forest (TAFV), Reston (RESTV) and Bundibugyo (BDBV) viruses.
The Marburgvirus genus comprises of a single species, Marburg
marburgvirus, of which several strains have been reported, includ-
ing its prototype virus Marburg virus (MARV) [1]. Infection with
EBOV and MARV results in a rapidly fatal hemorrhagic fever in
humans with reported case fatality rates of up to 90% [2,3].Currently, there is no approved treatment for EBOV or MARV
hemorrhagic fever beyond palliative care [4].
Attachment and entry of ﬁloviruses into target cells is mediated
by the viral glycoprotein (GP), which is the sole viral protein
exposed on the virion surface [5]. The GP is post-translationally
cleaved into two subunits, GP1 and GP2, both of which form a
trimer of heterodimers. The ﬁlovirus GP is composed of a heavily
glycosylated mucin domain and glycan cap region, which form a
deep, heavily glycosylated, chalice-like structure that encloses
the putative receptor-binding domain [6].
To date most research evaluating the potential of passive anti-
body transfer as a therapy for ﬁlovirus infections has focused on
EBOV infections. Neutralizing antibodies that target the EBOV-GP
have proven effective in protecting mice, guinea pigs and more
recently non-human primates (NHP) from lethal EBOV challenge
[7–12], while neutralizing monoclonal antibodies (MAbs) against
MARV GP were shown to confer only partial protection in guinea
pigs [13].
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against EBOV and MARV, and show that both MAbs protect against
lethal EBOV or MARV challenge in mice and/or guinea pigs.2. Materials and methods
2.1. Ethics statement
Approval for animal experiments was obtained from the Institu-
tional Animal Care and Use Committees at Rocky Mountain Labo-
ratories, DIR, NIAID, NIH and the University of Texas Medical
Branch. Animal work was performed by certiﬁed staff in an Associ-
ation for Assessment and Accreditation of Laboratory Animal Care
(AAALAC) approved facility. Animal housing, care and experimen-
tal protocols were in accordance with NIH guidelines.
2.2. Viruses and cells
Wildtype (WT) EBOV (strain Mayinga) was kindly provided by
the Special Pathogens Branch of the Centers for Disease Control
and Prevention, Atlanta, Georgia, United States, mouse adapted
(MA)-EBOV (strain Mayinga) and guinea pig adapted (GPA-) EBOV
(strain Mayinga) were kindly provided by United States Army
Medical Research Institute of Infectious Diseases, Frederick, MD,
US and WT MARV (strain Angola) and GPA-MARV (strain Angola)
were kindly provided by Public Health Agency of Canada, Winni-
peg, Canada. Generation of recombinant VSV expressing EBOV-GP
and MARV-GP has been described previously [14]. All viruses were
grown in Vero E6 cells in Dulbeccos modiﬁed eagles medium
(DMEM) supplemented with 2% Fetal Bovine Serum (FBS) and
antibiotics. Hybridoma cells were grown in DMEM supplemented
with 20% FBS, antibiotics, L-glutamine, and 10 mM HEPES at 37 C
and 5% CO2. All work was performed in a class II biological safety
cabinet. All work with live EBOV or MARV was performed under
biosafety level 4 conditions at the Integrated Research Facility,
Division of Intramural Research, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Hamilton, Mon-
tana and the Galveston National Laboratory, University of Texas
Medical Branch, Galveston, Texas.
2.3. Generation of antibody producing hybridomas
The neutralizing MAbs were generated through a project origi-
nally designed to induce cross-reactive MAbs. Therefore, groups of
BALB/c mice were vaccinated with 3  105 plaque forming units
(PFU) rVSV/EBOV-GP. Three weeks after vaccination, mice were
boosted with 3  105 rVSV/SUDV-GP or rVSV/MARV-GP to induce
a memory response against cross-reactive epitopes. Three days
after boost the mice were sacriﬁced, spleens harvested, and hybrid-
omas generated as described previously [15]. Brieﬂy, mouse
plasma cells were fused with SP2/0-Ag14 myeloma cells (ATCC).
Hybridomas were selected using HAT/HT selection medium.
Monoclonal hybridomas were isolated by two rounds of limiting
dilutions in 96 well ﬂat bottom tissue culture plates. Isolated
hybridomas were screened for secreted antibodies using a soluble
transmembrane deleted trimeric glycoprotein of EBOV, SUDV,
RESTV, TAFV, BDBV and MARV via indirect ELISA as previously
described [16]. Plasmids for soluble GP were kindly provided by
Dr. Ayato Takada.
2.4. Monoclonal antibody puriﬁcation
Antibody was puriﬁed from hybridoma cell culture supernatant
by concentration using Amicon plus-70 30,000 MWCO centrifugal
concentrators followed by protein A/G puriﬁcation columns(Thermo Scientiﬁc) according to manufacturer’s guidelines. Anti-
body was buffer exchanged into PBS using an Amicon 15 ml cen-
trifugal spin concentrator. Puriﬁed antibody concentrations were
determined by Bradford Protein Assay Reagent (Thermo Scientiﬁc).
2.5. Plaque reduction assay
MAbs were serially diluted twofold in DMEM and added to
100 plaque forming units (PFU) of rVSV/EBOV-GP, rVSV/MARV-
GP, WT EBOV or WT MARV and incubated for 1 h at 37 C. The
MAb/virus mix was used to infect monolayers of VeroE6 cells for
1 h at 37 C. Following adsorption, the inoculum was removed
and the cells were overlaid with 0.8% agarose/MEM/10% FBS. Cells
were incubated for two days with rVSV or 5–7 days or WTMARV or
EBOV, respectively, after which cells were stained with crystal vio-
let and plaques counted. Neutralization was calculated as the %
reduction in plaques as compared to untreated virus.
2.6. Western blotting
Puriﬁed soluble EBOV- and MARV-GP samples were analyzed by
SDS–PAGE using 10% acrylamide gel and transferred onto Hybond-
P PVDF Membrane (GE Healthcare) utilizing a Bio-Rad, Trans-Blot
SD Semi-Dry Transfer Cell following the manufacturer’s instruc-
tion. The membrane was blocked with 5% non-fat milk PBS/0.1%
tween overnight at 4 C and incubated with 2 lg/ml S9 or M4
MAb diluted in 5% non-fat milk/PBS-T for 1 h. The membrane
was then washed three times in PBS-T and incubated with anti-
mouse HRP antibody (1:25000; Jackson Immunoresearch), for 1 h
at room temperature. Following a ﬁnal washing step the binding
of antibody to the membrane was detected by ECL Plus Western
Blotting Detection Reagent and Hyperﬁlm ECL (GE Healthcare,
Amersham).
2.7. Escape mutants
Escape mutants were generated by incubating 105 TCID50 rVSV/
EBOV-GP or rVSV/MARV-GP with a sub-neutralizing amount (5 lg/
ml) of MAb S9 or M4 for 1 h at 37 C. The mixture was then inoc-
ulated onto a monolayer of Vero E6 cells for 1 h at 37 C. Cultures
were checked for CPE and viruses that escaped neutralization were
then passaged two additional times in the presence of MAb until
resistant viruses were obtained. Neutralization escape mutants
were plaque puriﬁed in the presence of MAb, and RNA from six
individual plaques was isolated using TRIzol Reagent (Life Technol-
ogies) according to the manufacturer’s guidelines. The GP gene was
ampliﬁed from the viral RNA using primers ﬂanking this gene in
the rVSV backbone by RT-PCR and sequenced.
2.8. Peptide epitopes
Overlapping synthetic pin peptides for the complete amino acid
sequence of EBOV-GP (GenBank accession number NP_066246.1)
were synthesized on pins as 15-mer peptides with a 10-mer over-
lap of each peptide (PepScan Presto). The pins were used to deter-
mine the linear binding epitope of antibodies. Brieﬂy, pins were
blocked with 1% Skim milk (Bio-Rad) + 1% Tween-20 (Fisher) in
0.01 M PBS in a Nunc round-bottom 96 well plate for 2 h at room
temperature then washed in 0.9% w/v NaCl and 0.05% v/v Tween-
20 in PBS (pH 7.2). Concentrated hybridoma supernatant for mAbs
were diluted 1:1 in 0.1% Skim milk + 0.1% Tween-20 in 0.01 M PBS
and added to a new ﬂexible Falcon 96 well plate and the pins were
incubated over night at 4 C in the antibody solution. Next, the pins
were washed as described above and an appropriate dilution of a
goat anti-mouse IgG-HRP secondary antibody (Southern Biotech)
in 0.1% Skim milk + 0.1% Tween-20 was incubated with the pins
C.D. Marceau et al. / Trials in Vaccinology 3 (2014) 89–94 91for 1 h at room temperature. Pins were washed as before and then
developed in ABTS solution (Roche) and incubated at room temper-
ature while color development was monitored. The plate was read
at 30 and 60 min at 405 nm by use of a SpectroMax250 Spectrom-
eter (Molecular Devices), and recorded by SoftMax Pro 4.6
Software (Molecular Devices). Pins were cleaned for subsequent
analysis according to commercial instructions.
2.9. Structural mapping of epitope
The peptides identiﬁed using the pepscan method were mapped
onto the crystal structure of EBOV-GP1 (PDB id: 3CSY) [6]. Since the
coordinates from K190 to Y213 (segment1) and N278 to R299 (seg-
ment2) are missing in the crystal structure of EBOV-GP1, these seg-
ments were modeled onto the existing EBOV-GP1 crystal structure
based on homology with other proteins. Brieﬂy, the sequence of
EBOV (GenBank id: NP_066246.1) was submitted to a fold recogni-
tion server to ﬁnd a suitable template structure for the missing
segments. In the absence of a good template structure, segment1
was modeled as a random loop structure, while segment2 was
modeled based on homology with PDB id: 3DSL [17]. Finally, the
MPACK program was used to build the complete model structure
of EBOV-GP1 by combining the two template structures (PDB id:
3CSY and 3DSL), similar to previous 3D modeling efforts in our
group [18,19]. The model structure of EBOV-GP1 was energy min-
imized using Fantom program [20]. The overall root-mean-square
deviation (r.m.s.d.) between model and crystal structure of
EBOV-GP1 protein was found to be 0.32 A. Figures were generated
using the PyMOL Molecular Graphics System, Version 1.5.0.4
Schrödinger, LLC.
2.10. Animal experiments
Groups of 6 female BALB/c mice (6 weeks of age) as well as 4
female Hartley guinea pigs (about 250 g) were obtained from
Charles River Laboratories and housed in HEPA-ﬁltered micro-
isolator cage systems. Mice were infected with 500 lethal dose
50% (LD50) of MA-EBOV by the intraperitoneal (IP) route. On days
1, 0, 1, 2, 3 post-infection, groups of 6 mice were given a single
injection of 250 lg/mouse puriﬁed MAb S9 via the IP route. Mice
were weighed daily and monitored for clinical signs of disease up
to 34 days after challenge. All surviving animals were euthanized
and bled on day 34 post challenge. Groups of 4 guinea pigs were
infected with 500 LD50 of GPA-EBOV (10 focus-forming units)
or GPA-MARV (1000 Tissue Culture Infectious Dose 50%) via the
IP route. On days 0, 1, 2 or 3 animals received a single dose of
MAb S9 or M4, respectively, (5 mg per animal) in 5 ml PBS via
the IP route. Animals were monitored for development of clinical
signs and weight loss daily until day 14. Surviving animals were
euthanized at day 21.3. Results
3.1. Identiﬁcation of neutralizing antibodies
Mice were primed with rVSV/EBOV-GP, followed by a boost
with rVSV/SUDV-GP or rVSV/MARV-GP. Two potent neutralizing
MAbs were identiﬁed during initial screening, one against EBOV
(S9) and one against MARV (M4). To determine the potency of neu-
tralization, as well as the cross-neutralizing potential of the two
monoclonal antibodies, a plaque reduction assay was performed.
MAb S9 neutralized rVSV/EBOV-GP (Fig. 1A), but no other rVSVs
pseudotyped with GPs derived from distinct Ebolavirus species
(SUDV, RESTV, TAFV, BDBV; data not shown). MAb S9 showed
50% neutralization at 1 lg/ml and 90% neutralization at 4 lg/ml.MAb M4 not only potently neutralized rVSV/MARV-GP (Angola
strain), but also rVSVs pseudotyped with GPs derived from distinct
MARV strains (Musoke, Ozolin and Ravn) (Fig. 1B). M4 showed 50%
neutralization at 0.1 lg/ml and 90% neutralization at 0.6 lg/ml.3.2. Neutralizing epitope characterization
To evaluate if MAbs S9 and M4 bind conformational or linear
epitopes, binding to EBOV- or MARV-GP was determined by Wes-
tern blot under reducing conditions eliminating conformational
epitopes. The western blot analysis revealed a band at 140 kDa,
the expected size of the GP1 subunit [21], for S9 but not for M4
(Fig. 2), while neither antibody reacted with GP2 (26 kDa). These
data suggest that MAb S9 recognizes a linear epitope on EBOV
GP1, whereas MAbM4most likely recognizes a conformational epi-
tope on the MARV GP. To further characterize the linear epitope of
S9, Pepscan’s CLIPS epitope mapping technology was used. Pep-
scan’s CLIPS Epitope Mapping technology utilizes synthesized,
overlapping, structurally constrained peptides that cover the entire
sequence of the EBOV GP. MAb S9 reacted strongest with the
EBOV-GP peptide sequence TKKNLTRKIRSEELSC, at an Optical Den-
sity of 0.439, which corresponds to positions 293–307 on the GP1
subunit of the glycoprotein. Interestingly, alignment of this epitope
domain in EBOV with those from RESTV, BDBV, TAFV and SUDV
shows up to 60% divergence between EBOV and RESTV (Table 1).
To further characterize the binding site of MAbs S9 and M4,
rVSV/EBOV-GP and rVSV/MARV-GP were grown in the presence
of MAb M4 or S9 to select for antigenic variants that escape MAb
mediated neutralization. No escape mutant could be generated
using the MAb M4 after 3 independent attempts. In contrast, six
plaque puriﬁed escape variants were sequenced for S9 and all
had a single mutation of G to A at nucleotide position 811 of the
EBOV-GP resulting in an amino acid substitution from glycine (G)
to arginine (R) at position 271 located in the glycan cap region of
GP1 (Fig. 3A and B). This neutralization escape mutation at
G271R is in close proximity to the N-terminus of the EBOV-GP pep-
tide sequence on the EBOV-GP crystal structure.3.3. Neutralizing antibody protects mice and guinea pigs from a lethal
ﬁlovirus challenge
The therapeutic potential of MAb S9 was ﬁrst evaluated in a
mouse model. All mice treated with a single dose of MAb S9 start-
ing on days 1, 0, 1 or 2 survived a lethal challenge with MA-EBOV
(Fig. 4). However, mice treated with MAb S9 starting 3 days post-
exposure did not show signiﬁcantly prolonged time to death and
succumbed to infection 5–8 days post infection similar to Mock
(PBS)-treated animals (Fig. 4).
To further evaluate the efﬁcacy of MAb S9 and to determine the
efﬁcacy of MAb M4 we tested the therapeutic efﬁcacy of these
antibodies in a lethal guinea pig model for both EBOV and MARV.
A single dose of MAb S9 conferred complete protection to all
EBOV-infected guinea pigs treated directly following infection
(Fig. 5A). Additionally, MAb S9 displayed efﬁcacy in protecting half
of the guinea pigs from a lethal GPA-EBOV challenge when admin-
istered up to one day post-infection and increased the time to
death up to 3 days (Fig. 5A). A single dose treatment with MAb
M4 protected guinea pigs challenged with a lethal dose of GPA-
MARV when administered up to 3 days after infection. All (100%)
challenged animals were protected when treated at the time of
infection; whereas 50–75% of the animals were protected when
MAb M4 was administered up to 3 days post infection (Fig. 5B).
No signiﬁcant difference in protective efﬁcacy was observed
between animals treated 1, 2 or 3 days post infection.
Fig. 1. Neutralization of EBOV and MARV strains by S9 and M4 monoclonal antibodies by plaque reduction assay. Shown are the percentages of plaque reduction of EBOV
(Mayinga strain) and MARV (Angolan, Musoke, Ozolin and Ravn strains) by S9 and M4, respectively, compared to untreated controls. Error bars represent standard deviations
from triplicates.
Fig. 2. Reactivity of MAbs M4 and S9 with linear epitopes on the GP. Shown is the
Western blot analysis of M4 and S9 MAb binding to recombinant soluble forms of
MARV- or EBOV-GP. Expected sizes of GP1 and GP2 are marked at 140 and 26 kDa,
respectively.
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Promising prophylactic treatments using antibodies against
EBOV have been explored using small rodent models, and more
recently with NHP challenged with EBOV. The best characterized
neutralizing MAb, KZ52, was derived from a human survivor of
the 1995 Kikwit EBOV outbreak [8]. The crystal structure of KZ52
was solved in complex with the EBOV-GP [6]. KZ52 binds to ungly-
cosylated regions on both GP1 and GP2 at the base of the chalice-
like structure of the GP. Clamping of GP1 and GP2 subunits by
KZ52 neutralizes the virion by inhibiting essential conformational
changes of the glycoprotein that facilitate fusion of the viral mem-
brane with the host cell membrane [22]. This antibody showed
efﬁcacy in pre- and postexposure prophylaxis in a guinea pigTable 1
Ebolavirus amino acid sequence variation in S9 epitope. Shown is the amino acid sequence
(SUDV) and Bundibugyo (BDBV) viruses. ⁄ = identical amino acid.
Virus GenBank Epitope
EBOV U23187 T K K N L T
RESTV U23152 ⁄ ⁄ ⁄ ⁄ F S
TAFVV U28006 N ⁄ ⁄ ⁄ F ⁄
SUDV U28134 ⁄ ⁄ ⁄ ⁄ ⁄ S
BDBV FJ217161 N ⁄ ⁄ ⁄ F ⁄model, but failed to protect against lethal challenge in a NHP
model [8,23]. Mouse-derived neutralizing MAb 133/3.16 binds a
linear epitope that likely overlaps with KZ52 located at the base
of the EBOV GP chalice [24]. MAb 226/8.1 binds a conformational
epitope comprising GP residues 134, 194, and 199 in the vicinity
of the cathepsin cleavage site [24,25]. The recently described
MB-003 MAb cocktail contains 3 MAbs that are believed to target
various regions within the mucin domain [26]. Finally another
cocktail of 3 MAbs designated ZMAb is believed to target the base,
the GP2 and the mucin domain [27]. These neutralizing MAbs and
others have been shown to protect mice, guinea pigs and NHP from
a lethal EBOV challenge [9–12].
In this study, using multiple complimentary methods, we
generated and characterized the neutralizing MAbs M4 and S9,
which bind to the GP of MARV and EBOV, respectively. In order
to identify the neutralizing epitopes recognized by MAbs, we and
others have previously employed neutralization escape mutant
analysis [25,28,29]. While we were unable to recover infectious
MARV during passage in the presence of MAb M4, we were
successful in identifying a G271R change in the EBOV-GP as a cor-
relate of neutralization escape to MAb S9. Further analysis through
western blot and pepscan epitope mapping suggests that the epi-
tope recognized by MAb S9 is linear and comprises of residues at
positions 293–307.
Together these data suggest that the G271R change caused an
opposing interaction between the positively charged R and the
neighboring positively charged K, thus likely rearranging the con-
formation on the surface of the GP1 portion of the epitope causing
disruption of the MAb S9 binding site on GP1. The mechanism of
neutralization of MAb S9 is most likely due to direct blocking of
the virus–receptor interaction. Since recent studies have shown
that neutralizing antibodies can protect against lethal EBOV
challenge in a variety of species including guinea pigs and NHP
[8–12,30]. We used a well established mouse model of lethal EBOV
infection [30] to show that MAb S9 protects mice completely fromalignment of the S9 epitope for Zaire (EBOV), Reston (RESTV), Tai Forest (TAFV), Sudan
R K I R S E E L S
Q Q L H G ⁄ N ⁄ H
K T L S ⁄ ⁄ ⁄ ⁄ ⁄
E Q L ⁄ G ⁄ ⁄ ⁄ ⁄
K T L S ⁄ ⁄ ⁄ ⁄ ⁄
Fig. 3. Location of the S9 epitope on the EBOV-GP structural model. Shown is the structural mapping of the S9 epitope on a cartoon representation (A) and surface view (B)
based on escape mutation (residue 271 in yellow) and Pepscan analysis (residues 293–307 in red).
Fig. 4. Prophylactic treatment of lethal EBOV infection in mice with S9. Shown is
the percentage of survivors of mouse-adapted EBOV infected mice treated with a
single dose of S9 (250 lg) at various days post challenge (n = 6 per treatment).
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infection demonstrating both a prophylactic and therapeutic use of
MAb S9. Additionally, MAb S9 completely protected guinea pigs
when treated the day of infection, and provided partial protection
up to 2 days post infection. Interestingly, protective efﬁcacy up to
3 days post infection was observed by increasing the time to death.
These data suggest that post-exposure treatment with MAb S9Fig. 5. Prophylactic treatment of lethal ﬁlovirus infection in guinea pigs with S9 and M4
guinea pig-adapted EBOV (A) or MARV(B) and treated with a single dose of S9 or M4 (5would increase the therapeutic window and could be combined
with other treatments such as RNA interference [31] or interferon
treatment [32]. Since MAb S9 is a neutralizing antibody with a
binding site on the glycan cap that is distinct from most other pre-
viously published neutralizing antibodies that primarily bind the
base subdomain or mucin domain [6,25,27], we believe MAb S9
would also be a good candidate for inclusion in a neutralizing
MAb cocktail that could provide broad prophylactic and therapeu-
tic protection against EBOV infections in NHP.
To date there has been limited information on neutralizing
MAbs directed against different MARV strains [13]. Here we report
a potent neutralizing MAb M4 that is likely directed against a con-
formational epitope on MARV-GP. The fact that no neutralization
escape mutant could be generated, suggests that MAbM4 is target-
ing an area on the MARV GP that is crucial for virus entry and/or
viability. This antibody is capable of potently cross neutralizing dif-
ferent MARV isolates at nanomolar concentrations. Additionally,
this antibody protects guinea pigs from a lethal challenge of MARV
with efﬁcacy up to 3 days post-infection. Given the recent success
of antibody treatment against EBOV, the M4 neutralizing antibody
will be a promising candidate for passive prophylactic therapy
against MARV infections in NHPs.
In conclusion, we have identiﬁed two novel neutralizing MAbs
against EBOV and MARV that provide prophylactic and therapeutic. Shown is the percentage of survival in groups of guinea pigs (n = 4) infected with
mg) at various days post challenge.
94 C.D. Marceau et al. / Trials in Vaccinology 3 (2014) 89–94protection against lethal infection in animals. These MAbs are
attractive candidates for inclusion in MAb cocktails to provide
broad protection against multiple EBOV species and MARV strains.
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